Pharvaris reports injectable-like efficacy from once-daily oral pill for rare genetic disease
read at Endpoints ↗Positive readoutPositive
Pharvaris announced that its experimental oral formulation of deucrictibant achieved efficacy comparable to injectable versions in a once-daily pill.
The drug is an extended-release version intended to prevent swelling attacks in patients with a rare genetic disorder, offering a more convenient treatment option.
The company said the data represent a pivotal readout that could advance the candidate toward later-stage development, and its stock rose sharply following the news.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Pharvaris' stock jumps on pivotal success in rare genetic disease”
read at Endpoints ↗85 words · retrieved Sep 8
comments(0)
5-min edit window · permanent after that